Street Capital Inc. (REZNF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Street Capital Inc. (REZNF) trades at $0.0002 with AI Score 43/100 (Grade C). Street Capital Inc. operates within the specialty and generic drug manufacturing sector. The company currently has a negative price-to-earnings ratio and profit margin. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for REZNF: REZNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates REZNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
REZNF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Street Capital Inc. (REZNF) Healthcare & Pipeline Overview
Street Capital Inc., a player in the specialty and generic drug manufacturing industry, faces challenges with profitability, indicated by its negative P/E ratio and profit margin. Operating within the healthcare sector, the company's performance is influenced by market dynamics and competitive pressures.
What Is the Investment Thesis for REZNF?
Street Capital Inc. presents a speculative investment opportunity within the specialty and generic drug manufacturing sector. With a market capitalization of $0.00B and a negative P/E ratio of -3.34, the company's financial performance raises concerns. However, a gross margin of 57.4% indicates potential in its core operations if profitability can be achieved. Key value drivers include successful development and commercialization of new drugs, strategic partnerships, and cost-efficiency improvements. Ongoing catalysts involve potential regulatory approvals and market expansion opportunities. Potential risks include competition, regulatory hurdles, and financial instability. Investors should closely monitor the company's progress in improving profitability and achieving sustainable growth.
Based on FMP financials and quantitative analysis
REZNF Key Highlights
Market Cap of $0.00B indicates a small-cap company with potential for growth but also higher risk.
- P/E Ratio of -3.34 suggests the company is currently not profitable.
- Profit Margin of -75.8% highlights significant challenges in achieving profitability.
- Gross Margin of 57.4% indicates a strong potential for profitability if operational efficiencies are improved.
- Beta of 0.74 suggests the stock is less volatile than the overall market.
Who Are REZNF's Competitors?
REZNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REZNF's Key Strengths?
Potential for high gross margin (57.4%).
- Established presence in the Canadian market.
- Focus on specialty and generic drugs.
- Relatively low beta (0.74) indicating lower volatility.
What Are REZNF's Weaknesses?
Negative P/E ratio (-3.34) indicating lack of profitability.
- Negative profit margin (-75.8%) indicating significant financial challenges.
- Small market capitalization ($0.00B) limiting access to capital.
- Limited information available about the company's operations.
What Could Drive REZNF Stock Higher?
Potential regulatory approvals for new drug formulations.
- Strategic partnerships to expand market reach.
- Cost-efficiency measures to improve profitability.
What Are the Key Risks for REZNF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger pharmaceutical companies.
- Regulatory hurdles and compliance requirements.
- Pricing pressures and reimbursement challenges.
- Negative P/E ratio and profit margin indicating financial instability.
- Shell Risk detected.
What Are the Growth Opportunities for REZNF?
- Expansion into New Therapeutic Areas: Street Capital Inc. can explore opportunities to expand its product portfolio into new therapeutic areas with unmet medical needs. This could involve developing or acquiring drugs targeting specific diseases or conditions, thereby increasing its market reach and revenue potential. The global market for specialty drugs is projected to reach $400 billion by 2028, presenting a significant growth opportunity for the company. Timeline: 2-3 years.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller, innovative drug developers can provide Street Capital Inc. with access to new technologies, products, and markets. This can accelerate its growth and enhance its competitive position. The pharmaceutical industry is witnessing increased consolidation, with mergers and acquisitions valued at over $200 billion annually. Timeline: 1-2 years.
- Geographic Expansion into Emerging Markets: Expanding its geographic presence into emerging markets, such as Asia and Latin America, can provide Street Capital Inc. with access to new customer bases and growth opportunities. These markets are experiencing rapid growth in healthcare spending and demand for generic drugs. The emerging markets pharmaceutical market is projected to reach $500 billion by 2030. Timeline: 3-5 years.
- Development of Proprietary Drug Formulations: Investing in the development of proprietary drug formulations or drug delivery technologies can differentiate Street Capital Inc. from its competitors and create a competitive advantage. This can involve developing novel formulations of existing drugs or improving drug delivery methods to enhance efficacy and patient compliance. The market for drug delivery technologies is projected to reach $100 billion by 2027. Timeline: 2-4 years.
- Focus on Cost-Efficiency and Operational Excellence: Implementing cost-efficiency measures and improving operational excellence can enhance Street Capital Inc.'s profitability and competitiveness. This can involve streamlining manufacturing processes, optimizing supply chain management, and reducing administrative expenses. The pharmaceutical industry is facing increasing pressure to reduce costs and improve efficiency. Timeline: Ongoing.
What Are REZNF's Competitive Advantages?
- Proprietary drug formulations or drug delivery technologies (if any).
- Established relationships with wholesalers and distributors.
- Regulatory expertise and compliance capabilities.
- Cost-efficient manufacturing processes.
What Does REZNF Do?
Street Capital Inc. is a Canadian company operating in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic drugs. While detailed information regarding its founding story and evolution is not available, the company's current market position is characterized by a small market capitalization. Street Capital Inc.'s operations are influenced by the dynamics of the pharmaceutical industry, including regulatory requirements, research and development costs, and competition from other drug manufacturers. The company's geographic reach is primarily within Canada, and its competitive positioning is shaped by its ability to develop, manufacture, and market specialty and generic drugs effectively. The company's financial performance, as indicated by its negative profit margin, suggests potential challenges in achieving profitability within the competitive pharmaceutical landscape. Further details on specific products, services, and strategic initiatives are needed to provide a more comprehensive understanding of Street Capital Inc.'s operations and future prospects.
What Products and Services Does REZNF Offer?
- Develops and manufactures specialty and generic drugs.
- Markets and distributes pharmaceutical products.
- Conducts research and development activities.
- Seeks regulatory approvals for new drugs.
- Forms strategic partnerships with other pharmaceutical companies.
- Manages its supply chain and distribution network.
- Monitors and complies with industry regulations.
How Does REZNF Make Money?
- Develops or acquires rights to specialty and generic drug formulations.
- Manufactures drugs in-house or through contract manufacturers.
- Sells drugs to wholesalers, distributors, and pharmacies.
- Generates revenue from drug sales.
What Industry Does REZNF Operate In?
Street Capital Inc. operates in the Drug Manufacturers - Specialty & Generic industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, regulatory scrutiny, and the need for continuous innovation. Market trends include increasing demand for generic drugs, rising healthcare costs, and advancements in drug delivery technologies. Street Capital Inc. competes with other generic drug manufacturers, as well as larger pharmaceutical companies. The company's success depends on its ability to develop and market cost-effective drugs, navigate regulatory hurdles, and maintain a competitive edge in the market.
Who Are REZNF's Key Customers?
- Wholesalers and distributors of pharmaceutical products.
- Pharmacies and retail drug stores.
- Hospitals and healthcare providers.
- Patients who purchase prescription drugs.
Financial Health
Street Capital Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
REZNF Valuation & Market Position
Relative to its peer group, REZNF's quantitative score of 43/100 is below the peer average of 62/100.
Key Financial Metrics
Return on equity for Street Capital Inc. stands at 205.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.36 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -30.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Street Capital Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Chris Savoie. REZNF has traded publicly since 2021.
REZNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting the potential for expansion in the mortgage market.
- Analysts have noted improvements in operational efficiency, which could lead to better profit margins moving forward.
- The real estate sector is showing signs of recovery, which could benefit Street Capital as they navigate through a more favorable lending environment.
Bear Case
- There are concerns about rising interest rates, which could dampen mortgage demand and impact Street Capital's business model negatively.
- Recent community discussions have raised red flags about regulatory challenges that could affect profitability in the long term.
- The company's stock performance has lagged behind peers, leading to skepticism among investors about its competitive positioning.
- Market sentiment remains cautious due to broader economic uncertainties, making investors wary of financial institutions like Street Capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
REZNF Latest News
No recent news available for REZNF.
REZNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REZNF.
Price Targets
Wall Street price target analysis for REZNF.
REZNF MoonshotScore
What does this score mean?
The MoonshotScore rates REZNF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Chris Savoie
CEO
Chris Savoie serves as the CEO of Street Capital Inc. Detailed information regarding his career history, educational background, and previous roles is not available. However, as CEO, he is responsible for leading the company's strategic direction, overseeing its operations, and driving its financial performance. His leadership is crucial in navigating the challenges and opportunities within the specialty and generic drug manufacturing industry.
Track Record: Information regarding Chris Savoie's specific achievements, strategic decisions, and company milestones under his leadership is not available. Assessing his track record requires further information on his tenure and the company's performance during his leadership.
REZNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Street Capital Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading may be subject to greater risks and volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier typically includes companies that are defunct, in bankruptcy, or unwilling to provide current information.
- OTC Tier: OTC Other
- Limited information and disclosure requirements.
- Higher risk of fraud and manipulation.
- Potential for delisting or suspension of trading.
- Thin trading volume and wide bid-ask spreads.
- Shell Risk Detected.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings.
- Consult with a financial advisor.
- Company has a functioning website.
- Presence of a CEO and management team.
- Operation in the healthcare sector.
- Gross margin above zero.
Street Capital Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for REZNF?
REZNF holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Street Capital Inc. operates within the specialty and generic drug manufacturing sector. The company currently has a negative price-to-earnings ratio and profit margin.
What does Street Capital Inc. do?
Street Capital Inc. operates within the healthcare sector, focusing on the development, manufacturing, and marketing of specialty and generic drugs. The company aims to provide cost-effective pharmaceutical products to meet the needs of patients and healthcare providers.
What do analysts say about REZNF stock?
Due to the limited information available and the company's OTC listing, analyst coverage for REZNF is likely minimal or non-existent. Key valuation metrics such as P/E ratio are currently negative, reflecting the company's lack of profitability. Growth considerations would depend on the company's ability to improve its financial performance, secure regulatory approvals for new drugs, and expand its market presence.
What are the main risks for REZNF?
The main risks for Street Capital Inc. include intense competition from larger pharmaceutical companies, regulatory hurdles and compliance requirements, pricing pressures and reimbursement challenges, and financial instability indicated by its negative P/E ratio and profit margin. Additionally, as an OTC-listed company, REZNF faces risks associated with limited information disclosure, thin trading volume, and potential for price manipulation.
What are the key factors to evaluate for REZNF?
Street Capital Inc. (REZNF) holds an AI score of 43/100 (low). presents a speculative investment opportunity within the specialty and generic drug manufacturing sector. Not financial advice.
How frequently does REZNF data refresh on this page?
REZNF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven REZNF's recent stock price performance?
Street Capital Inc. (REZNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Potential for high gross margin (57.4%). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider REZNF overvalued or undervalued right now?
Street Capital Inc. (REZNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research REZNF before investing?
Before investing in Street Capital Inc. (REZNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Street Capital Inc. The analysis is based on the available data and may not reflect the company's complete situation.